Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types.
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
Case report and literature review of ENKTL presenting with ocular symptoms and treated with GemOx
A Rare Eye Symptom Led Doctors Down the Wrong Path for Months
This case report and literature review describes a single patient with extranodal natural killer/T cell lymphoma presenting with ocular symp…
Double vision and sinus scans that looked clean hid a rare lymphoma that stole a man's sight after months of wrong treatments.
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone.
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma. The study compar…
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Gemcitabine exposure associated with higher TP53 and PI3K pathway alterations in pancreatic ductal adenocarcinoma tumors.
AI Finds Hidden Keys to Pancreatic Cancer Survival
This cohort study analyzed 184 pancreatic ductal adenocarcinoma tumors to assess the association between gemcitabine exposure and molecular …
Age and gemcitabine exposure drive distinct genetic patterns in pancreatic cancer, directly influencing survival rates for patients with key…
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations. Tumor r…
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Meta-analysis of intravesical gemcitabine/docetaxel versus BCG in non-muscle-invasive bladder cancer
A Two-Drug Bladder Wash May Rival the Gold Standard in Shortage
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel combination therapy versus Bacillus Calmette-Guéri…
A combination bladder rinse may match the standard treatment for early bladder cancer, which matters because BCG has been in short supply fo…
Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
Adding gemcitabine to cisplatin did not improve disease-free survival in bladder cancer patients.
A Phase II randomized trial in 69 patients with pT2-pT3N0M0 muscle-invasive bladder cancer found similar 2-year disease-free survival (58.3%…
Adding gemcitabine to cisplatin radiotherapy did not improve disease-free survival for bladder cancer patients, with similar two-year rates …
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus gem…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …